1)中国农业大学信息与电气工程学院,北京 100083;2)国家发展和改革委员会创新驱动发展中心,北京 100037
Tel:
1)College of Information and Electrical Engineering, China Agricultural University, Beijing 100083, China;2)Innovation Driven Development Center, National Development and Reform Commission, Beijing 100037, China
目的 随着生物产业的快速发展,越来越多的生物企业涌现,其中以生物医药企业为主。如何促进生物企业产出效率是政府和企业自身最关心的问题。方法 论文构建了生物产业上市企业绩效评估DEA模型,对全国370家生物产业上市企业的投入产出效率情况进行评估。结果 全国生物产业上市企业平均综合技术效率为0.596,还有很大进步空间。结论 制约中国生物产业上市企业综合技术效率的主要因素是纯技术效率;较大型生物产业上市企业应优化投入、减少冗余,较小型生物产业上市企业则需要扩大企业规模。
Objective With the rapid development of the bio-industry, more and more biological enterprises, mainly biomedical enterprises, have emerged. How to promote the output efficiency of biological enterprises is the most concern of the government and enterprises themselves.Methods This paper constructs a DEA model to evaluate the input-output efficiency of 370 listed companies in China’s biological industry.Results The research results show that the average comprehensive technical efficiency of listed companies in China"s biological industry is 0.596, and there is still much room for improvement.Conclusion The main factor restricting the overall technical efficiency of listed companies in China’s biological industry is pure technical efficiency. Large-scale listed biological companies should optimize investment and reduce redundancy, while smaller-scale listed biological companies need to expand their scale.
丁俊琦,白京羽,林晓锋.基于DEA模型的中国生物产业上市企业绩效评估[J].生物化学与生物物理进展,2022,49(2):431-437
复制生物化学与生物物理进展 ® 2025 版权所有 ICP:京ICP备05023138号-1 京公网安备 11010502031771号